LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its Strategic Advisory Board and the appointment of its ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

VP of global clinical development at Merck Research Laboratories, said in a statement. Although the LEAP-015 readout is technically positive given the trial’s dual primary endpoint design ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research ...

Merck Research Laboratories, in a press release. “ADCs have shown promise as an important modality in the treatment of different cancer types, and the initiation of this Phase III waveLINE clinical ...

HEIDELBERG, Germany, February 06, 2025 / Biotech Newswire / --German independent research institute BioMed X announces the successful completion of its oncology research project in partnership with ...

Merck Research Laboratories, in a press release. “Today’s US filing acceptance demonstrates our commitment to advancing novel therapies, such as Welireg, to help treat patients with certain rare ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

at Merck Research Laboratories: “We will continue to study Zepatier to understand even more about its role in treating chronic hepatitis C infection and will continue to work with others to help ...